中国国家医保谈判药品药物经济学评价研究的系统评价

The pharmacoeconomic analyses of the Chinese national drug negotiations: a systematic review

目的 系统评价中国国家医保谈判药品的药物经济学评价研究。方法 计算机检索PubMed、EMbase、The Cochrane Library、CNKI和WanFang Data数据库,搜集中国国家医保谈判药品的药物经济学评价研究,检索时限为2012年1月1日至2022年1月1日。由2名研究者独立筛选文献、提取资料并评价纳入研究的偏倚风险后,进行定性系统评价。结果 国家医保谈判药品有59种(33.9%)发表过药物经济学评价研究,涉及124篇文献。仅有23种(13.2%)药品在医保谈判前已有药物经济学评价研究发表,共29篇文献(23.3%)。所有已发表研究中,有75篇(60.5%)得出研究药物比对照药物更具经济性优势的阳性结论。结论 目前国家医保谈判药品的药物经济学评价研究仍存在不足,需进一步推动相关研究,为国家医保谈判提供证据支持。

Objective To systematically review the pharmacoeconomic studies of negotiated drugs in the Chinese National Reimbursement Drug List(NRDL). Methods PubMed, EMbase, The Cochrane Library, CNKI and WanFang Data databases were electronically searched to collect the pharmacoeconomic studies of negotiated drugs in the Chinese NRDL from January 1, 2012 to January 1, 2022. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies, then, the qualitative systematic review was performed. Results A total of 59(33.9%) drugs were evaluated in 124 pharmacoeconomic studies. Only 23(13.2%) drugs were evaluated in 29(23.3%)pharmacoeconomic studies prior to the negotiation. Besides, 75(60.5%) of the negotiated drugs were supported by evidence of economic superiority than the comparison. Conclusion The pharmacoeconomic studies on drugs which listed in the NRDL is insufficient. Future pharmacoeconomic studies should perform to provide more substantial support for the national drug negotiations.